UnitedHealth's Next Growth Test Is Whether Optum Health Can Restore Margins

UnitedHealth Group's clearest internal growth opportunity is Optum Health, which combines physician practices, ambulatory facilities and value-based care. The unit serves about 20 million patients, with roughly 4 million in fully accountable arrangements where Optum takes responsibility for both cost and outcomes.

That 20% penetration leaves room to move more patients into risk-based contracts. The model can reward coordinated primary care, home health, hospice and lower-cost surgery settings when those services prevent expensive hospital episodes. It can also magnify mistakes: if medical costs exceed the payments received, Optum bears more of the loss.

Scale alone has not produced a smooth financial trajectory. Optum Health represented about 22.8% of UnitedHealth's 2025 revenue, while Optum Rx was larger at 34.6%, before accounting for intersegment activity. Optum Health revenue fell 3.2% in 2025 after growing 10.5% in 2024. Management has set a multi-year operating-margin goal of 6% to 8%, which depends on better pricing, care management and capacity utilization.

The broader company expects at least $20.50 of adjusted earnings per share in 2026. Third-quarter disclosures also showed that commercial medical-cost trends were running above the initial 11% expectation. That matters because UnitedHealth cannot evaluate Optum's growth separately from the insurance business that often channels members into its care network.

Optum's opportunity is therefore a margin-and-quality story, not simply a patient-count story. Moving more people into accountable care can increase recurring revenue and deepen relationships with payers. Investors still need evidence that the company is pricing risk correctly and delivering care at lower total cost without sacrificing access or outcomes.

The most informative indicators will be the number of patients in fully accountable arrangements, Optum Health's organic revenue growth, operating margin and the difference between expected and actual medical costs. Progress on all four would support the growth thesis. Patient growth without margin recovery would not.